Episode Details

Cogent Biosciences, Inc. (COGT) Q2 2026 — Q2 2026 (three months ended June 30; the 8-K hit EDGAR at 08:06 ET on Monday August 10, so August 10 is the reaction session): no revenue at all, net loss 96.4M USD, GAAP loss per share 0.52 USD vs a 0.55 bar. The print moved the stock just 2.03 pct on 0.68x volume - then a 400M USD equity program was filed at 17:17 the same day and the next session fell 6.81 pct. Cogent has won. PEAK is the first positive Phase 3 in second-line GIST in over twenty years, three NDAs are filed and two PDUFA dates land inside twenty weeks. The stock is up 249 pct in a year. And at 17:17 on the afternoon it reported, Cogent registered another 400M USD of stock. THE CALL: HOLD (3/5, MODERATE - GREAT DRUG, FULL PRICE) — base-case value ~$26.14 vs ~$37.93 today. KEY METRICS: - CALL: HOLD, 3/5. Fair value 26.48 USD vs the 37.93 USD close on August 14 - about 30 pct BELOW the tape, and 45 pct below the 47.80 USD Street consensus. With no revenue and no earnings to put a multiple on, this is a probability-weighted NPV: bear 20.47, base 26.14, bull 33.15, weighted 25/50/25. Even the bull case sits below the price. - THE QUARTER (ended June 30, 2026): NO revenue line at all - the income statement opens at operating expenses. R and D 70.8M USD, up 13.8 pct. G and A 31.8M USD, up 137.9 pct on the commercial build. Net loss 96.4M USD, up 31.1 pct. Loss per share 0.52 USD via the TWO-CLASS method; a flat division gives 0.56 and is wrong. - THE ANGLE - THE PRICE OF THE WIN: on November 7, 2025, the Friday BEFORE the PEAK read-out, Cogent lifted its ATM ceiling from 75M to 300M USD. The Monday after, the stock rose 119 pct in one session. Eight days later it sold 230.0M USD of 1.625 pct converts at 44.95 USD with NO capped call - then filed a NEW 400M USD program on print day. - THE DILUTION, FULLY COUNTED: the 10-Q cover shows 173,524,982 shares at August 6, yet the screens print a 6,481M USD market cap - implying only 170.9M. Add preferred as-converted, 5.12M convert shares, 27.11M options at 11.08 USD, restricted stock and the new program: 235.6M claims, 35.8 pct more paper than the screen shows. - THE EVIDENCE IS GENUINELY STRONG: PEAK Phase 3 in second-line GIST gave median PFS of 16.5 months vs 9.2 on sunitinib alone, hazard ratio 0.50, and a 46 pct response rate vs 26 pct. APEX in advanced systemic mastocytosis: 65 pct response. But overall survival in PEAK is still IMMATURE, and survival is what payers price. - CASH AND RUNWAY: 792.3M USD at June 30 plus 73.6M raised since gives 865.9M USD pro forma, against 230.0M USD of converts. Operating burn was 164.2M USD across the half - 82.1M a quarter, or 10.5 quarters. Management guides into late 2028, but that assumes burn never rises through a launch. Runway and dilution are the same decision. What to watch: UP: approval on November 30 (GIST) and December 30 (non-advanced SM); the avapritinib-switch SUMMIT extension reading out by year end; the equity program left undrawn into strength. DOWN: a complete response letter on either filing; the 400M USD program drawn hard after approval; AYVAKIT holding share. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision. Learn investing free in the Charged Alpha app: https://chargedalpha.com/app?source=youtube&ref=video Educational only. Not financial advice.